Early gene expression changes with rush immunotherapy

Clinical and Molecular Allergy

David A Khan²  Sherry Ridz Barnett²  Sumit Bhutani²  Laurie S Davis¹ 

[1] Department of Internal Medicine, Division of Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX, 75390-8884, USA;Department of Internal Medicine, Division of Allergy and Immunology, University of Texas Southwestern Medical Center, Dallas, TX, 75390-8859, USA

关键词: gene expression;    allergy;    Rush immunotherapy;   

Others  :  790701
DOI  :  10.1186/1476-7961-9-12

 received in 2011-02-05, accepted in 2011-09-30,  发布年份 2011

【 摘 要 】

Background

To examine whether whole genome expression profiling could reveal changes in mRNA expression of peripheral blood mononuclear cells (PBMC) from allergic patients undergoing rush immunotherapy (RIT) that might be manifest within the first few months of treatment.

Methods

For this study, PBMC from three allergic patients undergoing RIT were assessed at four timepoints: prior to RIT, at 1 week and 7 week post-RIT, during build-up and at 4 months, after establishment of a maintenance dose. PBMC mRNA gene expression changes over time were determined by oligonucleotide microarrays using the Illumina Human-6 BeadChip Platform, which simultaneously interrogates expression profiles of > 47,000 transcripts. Differentially expressed genes were identified using well-established statistical analysis for microarrays. In addition, we analyzed peripheral blood basophil high-affinity IgE receptor (Fc epsilon RI) expression and T-regulatory cell frequency as detected by expression of CD3⁺CD4⁺CD25bright cells at each timepoint using flow cytometry.

Results

In comparing the initial 2 timepoints with the final 2 timepoints and analyzing for genes with ≥1.5-fold expression change (p less than or equal to 0.05, BH-FDR), we identified 507 transcripts. At a 2-fold change (p less than or equal to 0.05, BH-FDR), we found 44 transcripts. Of these, 28 were up-regulated and 16 were down-regulated genes. From these datasets, we have identified changes in immunologically relevant genes from both the innate and adaptive response with upregulation of expressed genes for molecules including IL-1β, IL-8, CD40L, BTK and BCL6. At the 4 month timepoint, we noted a downward trend in Fc epsilon RI expression in each of the three patients and increased allergen-specific IgG4 levels. No change was seen in the frequency of peripheral T-regulatory cells expressed over the four timepoints.

Conclusions

We observed significant changes in gene expression early in peripheral blood samples from allergic patients undergoing RIT. Moreover, serum levels for allergen specific IgG4 also increased over the course of treatment. These studies suggest that RIT induces rapid and dynamic alterations in both innate and adaptive immunity which can be observed in the periphery of allergic patients. These alterations could be directly related to the therapeutic shift in the allergen-specific class of immunoglobulin.

【 授权许可】

   
2011 Davis et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Akdis M, Akdis CA: Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2007, 119:780-91.
• [2]Thunberg S, Akdis M, Akdis CA, Grönneberg R, Malmström V, Trollmo C, van Hage M, Gafvelin G: Immune regulation by CD4+CD25+ T cells and interleukin-10 in birch pollen-allergic patients and non-allergic controls. Clin Exp Allergy 2007, 37:1127-36.
• [3]Till SJ, Durham SR: Immunologic responses to allergen immunotherapy. Clin Allergy Immunol 2004, 18:85-104.
• [4]Cox L: Accelerated immunotherapy schedules: review of efficacy and safety. Ann Allergy Asthma Immunol 2006, 97:126-37.
• [5]Muller U, Hari Y, Berchtold E: Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy. J Allergy Clin Immunol 2001, 107:81-6.
• [6]Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A, PREDICT-1 Study Team: HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008, 358:568-79.
• [7]Brugarolas J, Haynes BF, Nevins JR: Towards a genomic-based diagnosis. Lancet 2001, 357:249-50.
• [8]Mandel M, Achiron A: Gene expression studies in systemic lupus erythematosus. Lupus 2006, 15:451-6.
• [9]Morris SR, Carey LA: Gene expression profiling in breast cancer. Curr Opin Oncol 2007, 19:547-51.
• [10]Kaizer EC, Glaser CL, Chaussabel D, Banchereau J, Pascual V, White PC: Gene expression in peripheral blood mononuclear cells from children with diabetes. J Clin Endocrinol Metab 2007, 92:3705-11.
• [11]Vercelli D: Discovering susceptibility genes for asthma and allergy. Nat Rev Immunol 2008, 8:169-82.
• [12]Liu Z, Yelverton RW, Kraft B, Tanner SB, Olsen NJ, Aune TM: Highly conserved gene expression profiles in humans with allergic rhinitis altered by immunotherapy. Clin Exp Allergy 2005, 35:1581-90.
• [13]Konno S, Golden DB, Schroeder J, Hamilton RG, Lichtenstein LM, Huang SK: Level of osteopontin is increased after bee venom immunotherapy. J Allergy Clin Immunol 2005, 115:1317-8.
• [14]Prussin C, Griffith DT, Boesel KM, Lin H, Foster B, Casale TB: Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol 2003, 112:1147-54.
• [15]Harvey SM, Laurie S, Hilton K, Khan DA: Safety of rush immunotherapy to multiple aeroallergens in an adult population. Ann Allergy Asthma Immunol 2004, 92:414-9.
• [16]Spector SL, Nicklas RA, Chapman JA, Bernstein IL, Berger WE, Blessing-Moore J, Dykewicz MS, Fineman SM, Lee RE, Li JT, Portnoy JM, Schuller DE, Lang D, Tilles SA, Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma, and Immunology, American College of Allergy, Asthma, and Immunology, Joint Council of Allergy, Asthma, and Immunology: Symptom severity assessment of allergic rhinitis: part 1. Ann Allergy Asthma Immunol 2003, 91:105-14.
• [17]Wachholz PA, Durham SR: Mechanisms of immunotherapy: IgG revisited. Curr Opin Allergy Clin Immunol 2004, 4:313-8.
• [18]Kehrl JH: Chemoattractant receptor signaling and the control of lymphocyte migration. Immunol Res 2006, 34:211-27.
• [19]Mongini PK, Inman JK, Han H, Fattah RJ, Abramson SB, Attur M: APRIL and BAFF promote increased viability of replicating human B2 cells via mechanism involving cyclooxygenase 2. J Immunol 2006, 176:6736-51.
• [20]Polo JM, Ci W, Licht JD, Melnick A: Reversible disruption of BCL6 repression complexes by CD40 signaling in normal and malignant B cells. Blood 2008, 112:644-51.
• [21]Hammer M, Mages J, Dietrich H, Servatius A, Howells N, Cato AC, Lang R: Dual specificity phosphatase 1 (DUSP1) regulates a subset of LPS-induced genes and protects mice from lethal endotoxin shock. J Exp Med 2006, 203:15-20.
• [22]Lang R, Hammer M, Mages J: DUSP meet immunology: dual specificity MAPK phosphatases in control of the inflammatory response. J Immunol 2006, 177:7497-504.
• [23]Weinberg JB: Nitric oxide synthase 2 and cyclooxygenase 2 interactions in inflammation. Immunol Res 2000, 22:319-41.
• [24]Chambers DM, Rouleau GA, Abbott CM: Comparative genomic analysis of genes encoding translation elongation factor 1B(alpha) in human and mouse shows EEF1B1 to be a recent retrotransposition event. Genomics 2001, 77:145-8.
• [25]Mazuruk K, Schoen TJ, Chader GJ, Iwata T, Rodriguez IR: Structural organization and chromosomal localization of the human ribosomal protein L9 gene. Biochim Biophys Acta 1996, 1305:151-62.
• [26]Nishii Y, Morishima M, Kakehi Y, Umehara K, Kioka N, Terano Y, Amachi T, Ueda K: CROP/Luc7A, a novel serine/arginine-rich nuclear protein, isolated from cisplatin-resistant cell line. FEBS Lett 2000, 465:153-6.
• [27]Heishi M, Kagaya S, Katsunuma T, Nakajima T, Yuki K, Akasawa A, Maeda M, Gunji S, Sugita Y, Tsujimoto G, Saito H: High-density oligonucleotide array analysis of mRNA transcripts in peripheral blood cells of severe atopic dermatitis patients. Int Arch Allergy Immunol 2002, 129:57-66.
• [28]Benson M, Svensson PA, Carlsson B, Jernas M, Reinholdt J, Cardell LO, Carlsson L: DNA microarrays to study gene expression in allergic airways. Clin Exp Allergy 2002, 32:301-8.
• [29]Zhang RX, Yu SQ, Jiang JZ, Liu GJ: Complementary DNA microarray analysis of chemokines and their receptors in allergic rhinitis. J Investig Allergol Clin Immunol 2007, 17:329-36.
• [30]Moverare R, Vesterinen E, Metso T, Sorva R, Elfman L, Haahtela T: Pollen-specific rush immunotherapy: clinical efficacy and effects on antibody concentrations. Ann Allergy Asthma Immunol 2001, 86:337-42.
• [31]Jutel M, Akdis M, Blaser K, Akdis CA: Mechanisms of allergen specific immunotherapy--T-cell tolerance and more. Allergy 2006, 61:796-807.
• [32]Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St Groth B, Clayberger C, Soper DM, Ziegler SF, Bluestone JA: CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4 + T reg cells. J Exp Med 2006, 203:1701-11.
• [33]Samy ET, Setiady YY, Ohno K, Pramoonjago P, Sharp C, Tung KS: The role of physiological self-antigen in the acquisition and maintenance of regulatory T-cell function. Immunol Rev 2006, 212:170-84.
• [34]Holt P, Strickland DH: Interactions between innate and adaptive immunity in asthma pathogenesis: new perspectives from studies on acute exacerbations. J Allergy Clin Immunol 2010, 125:963-72.